A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
NCT03941574
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
108
Enrollment
INDUSTRY
Sponsor class
Conditions
MSI-H Solid Malignant Tumor
Interventions
DRUG:
HLX10
Sponsor
Shanghai Henlius Biotech